Mealey's (September 16, 2022, 10:18 AM EDT) -- WASHINGTON, D.C. — In a Sept. 7 reply brief supporting its petition for certiorari, generic drug maker Teva Pharmaceuticals USA Inc. tells the U.S. Supreme Court that the Federal Circuit U.S. Court of Appeals’ finding that it induced infringement of a congestive heart failure (CHF) drug patent belonging to GlaxoSmithKline LLC (GSK) “inroads foundational principles of patent law while upsetting a careful legislative compromise that ensures ready access to low-cost generic medicines.”...